5-[2-(1-Hydroxypropan-2-yloxy)-2-methoxyethoxy]-5-oxopentanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5-[2-(1-Hydroxypropan-2-yloxy)-2-methoxyethoxy]-5-oxopentanoic acid
• 英文别名: 5-[2-(1-hydroxypropan-2-yloxy)-2-methoxyethoxy]-5-oxopentanoic acid
• 化学式: C₁₁H₂₀O₇
• 分子量: 264.27
• InChiKey: SBMDSZDREURIRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  18
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• PROTEIN-POLYMER-DRUG CONJUGATES
  申请人：Mersana Therapeutics, Inc.

  公开号：US20150064130A1

  公开（公告）日：2015-03-05

  Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L D -D, the protein based recognition-molecule being connected to the polymeric carrier by L P . Each occurrence of D is independently an Auristatin compound. L D and L P are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

  本文提供了Auristatin化合物及其共轭物。该共轭物包括基于蛋白质的识别分子（PBRM）和多聚载体，该多聚载体被一个或多个-LD-D取代，其中，基于蛋白质的识别分子通过LP连接到多聚载体上。每个D的出现都是独立的Auristatin化合物。LD和LP是连接治疗剂和PBRM到多聚载体的连接器。还公开了用于与PBRM共轭形成描述的聚合物-药物-PBRM共轭物的聚合物支架，包括共轭物的组成，其制备方法以及使用共轭物或其组成物治疗各种疾病的方法。
• [EN] PROTEIN-POLYMER-DRUG CONJUGATES<br/>[FR] CONJUGUÉS PROTÉINE-POLYMÈRE-MÉDICAMENT
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2014093394A1

  公开（公告）日：2014-06-19

  A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by Lp. Each occurrence of D is independently a therapeutic agent having a molecular weight < 5 kDa. LD and Lp are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer- drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.